Key Takeaways:
Key Takeaways:
Stryker posted second-quarter results that topped Wall Street estimates, driven by surging demand for its surgical instruments, endoscopy systems and orthopedic implants as hospitals resumed elective procedures at elevated volumes.
"We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter," Kevin A. Lobo, chair and chief executive officer at Stryker, said. "With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum."
The Portage, Michigan-based medical device maker reported adjusted net earnings of $1.42 billion, or $3.69 per diluted share, in the three months ended June 30, up 17.6% from $1.21 billion, or $3.13 per share, a year earlier. That beat the $3.49 average analyst estimate compiled by Refinitiv. Revenue rose 9.4% to $6.59 billion, with organic sales — which strip out currency swings and acquisitions — climbing 9.0% on higher unit volume across both of its reporting segments.
Stryker's MedSurg and Neurotechnology unit, its largest segment, generated $3.63 billion in sales, up 9.7% from a year earlier, fueled by 13.4% growth in its Medical business, which includes patient handling and emergency care equipment. The Orthopaedics division posted $2.96 billion in revenue, a 9.1% increase, with trauma and extremities — a category that includes plates, screws and joint reconstruction systems — rising 11.9% to $1.07 billion. Hip replacement sales grew just 2.9%, the slowest among major product lines, while knee implants rose 8.4%.
The company's adjusted operating margin expanded to 27.4% from 25.7% a year ago, reflecting improved manufacturing efficiency and lower acquisition-related costs. Reported gross margin widened to 68.3% from 63.8%, helped in part by the reversal of $158 million in tariffs that had weighed on cost of sales in the prior-year period.
Stryker narrowed its full-year 2026 outlook, now projecting organic net sales growth of 8.3% to 9.3% and adjusted earnings per share of $14.95 to $15.10. The guidance range implies fourth-quarter adjusted EPS of roughly $3.73 to $3.88 at the midpoint, based on the company's year-to-date performance. Foreign exchange is expected to have a slightly favorable impact on both sales and earnings should current rates hold.
The results underscore a broader recovery across the medical device sector, where companies including Zimmer Biomet and Medtronic have also reported rebounding procedure volumes as surgical backlogs accumulated during the pandemic continue to clear. Stryker's performance suggests hospitals are investing in capital equipment and implant technologies even as they face persistent labor cost pressures. The company's $3.39 billion cash position and $3.74 billion in receivables provide ample liquidity to fund its $368 million in year-to-date capital expenditures and ongoing acquisition strategy.
Stryker shares have gained roughly 12% year-to-date, outperforming the S&P 500's health care equipment index. At current levels, the stock trades at about 24 times forward earnings, a premium to the broader med-tech peer group, reflecting the company's consistent above-market growth and margin trajectory.
This article is for informational purposes only and does not constitute investment advice.
